MRI Response Assessment in Glioblastoma Patients Treated with Dendritic-Cell-Based Immunotherapy.
Johanna HeugenhauserMalik GalijaševićStephanie MangesiusGeorg GoebelJohanna BuchroithnerFriedrich ErhartJosef PichlerGeorg WidhalmGünther StockhammerSarah IglsederChristian F FreyschlagStefan OberndorferKarin BordihnGord von CampeThomas CzechBirgit SurböckTadeja Urbanic PurkartChristine MarosiThomas FelzmannMartha NowosielskiPublished in: Cancers (2022)
When comparing different response-assessment criteria in GB patients treated with dendritic cell-based immunotherapy, the best correlation between PFS and OS was observed for mRANO and Vol-mRANO. Interestingly, iRANO was not superior for predicting OS in patients treated with Audencel.